Enumera Molecular is developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests.
Enumera Molecular has raised $12.5M in total funding. The most recent round was Series A. The last funding was announced in May 2022.
Enumera Molecular's investors include Arboretum Ventures.
Enumera Molecular is headquartered in Ann Arbor, United States.
Enumera Molecular is developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests.
Enumera Molecular is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Enumera Molecular — Funding & Investors." VCBacked, May 5, 2022, https://www.vcbacked.co/company/enumera-molecular. Accessed August 14, 2026.
VCBacked. (2022). Enumera Molecular — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/enumera-molecular
{{cite web |title=Enumera Molecular — Funding & Investors |url=https://www.vcbacked.co/company/enumera-molecular |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated